From research to business: Business Finland grants €1.3 million to two TAMK projects
Business Finland’s Research to Business funding supports the commercial exploitation of research-based innovations and the creation of international business.
Ari Sivula, Vice President for Research, Development and Innovation, considers two positive funding decisions from two submitted applications an excellent result.
“The fundings demonstrate the high quality of our research, development and innovation activities. We are identifying research results that have both societal impact and international business potential. These projects contribute to our strategic goal of expanding impactful RDI activities that renew working life”, says Sivula.
Smart analytics for improving indoor air and space utilisation
The first funded project focuses on smart analytics for indoor air quality and space utilisation. The solution is designed to simultaneously detect ventilation problems automatically, optimise the use of space and energy, and assess the risk of airborne infections in individual spaces.
“The solution is based on an intelligent algorithm developed at TAMK. It provides customers with data on ventilation performance, space utilisation rates and infection risks. The primary target for commercialisation is the European market, where the EU’s recently revised Energy Performance of Buildings Directive is increasing demand”, says Sampo Saari, Principal Lecturer.
New technology for screening peripheral arterial disease
The other funding was granted to IdCLTI project led by PRECISE research group. The multidisciplinary team aims to support the transition from reactive health care to a predictive, preventive, personalised and participatory (P4) approach that improves both the quality and cost-effectiveness of care.
The IdCLTI project develops automated, tissue-safe technology for population-level screening of peripheral arterial disease. The condition is a growing global health challenge, and its early stages often remain undetected.
“Our goal is to detect peripheral arterial disease earlier and more accurately than is currently possible. Earlier referral to treatment could help prevent severe tissue complications”, says Petra Korpisalo-Pirinen, Senior Researcher.
According to her, the research is based on new insights into capillary function in peripheral arterial disease of the lower extremities. Korpisalo-Pirinen believes that the solution has significant international commercial potential and it could positively affect patient wellbeing, health care systems and resources.
The project is also part of Business Finland’s Health 360 programme.
TAMK strengthens its role in research commercialisation
Both projects will start in August–September 2026 and run until summer 2028. The overall initiative strengthens Tampere University of Applied Sciences’ role in the commercialisation of applied research and supports the creation of new businesses and international operations.
At the same time, the projects build shared expertise between research and industry in technology commercialisation.
Additional information:
Petra Korpisalo-Pirinen
Senior Researcher | Social Services and Health care
Tampere University of Applied Sciences
petra.korpisalo-pirinen [at] tuni.fi (petra[dot]korpisalo-pirinen[at]tuni[dot]fi)
Sampo Saari
Principal Lecturer | Built Environment and Bioeconomy
Tampere University of Applied Sciences
sampo.saari [at] tuni.fi (sampo[dot]saari[at]tuni[dot]fi), +358 40 658 7553
